Sanstar Ltd Eyes Growth with Ingredion Partnership and ₹198.3 Crore Funding

Sanstar Limited will raise ₹198.3 crore through a preferential issue to Corn Products Development Inc., a subsidiary of global ingredient solutions leader Ingredion Incorporated. The issue price is ₹110 per equity share.

Reader Takeaway: Fresh capital and global partnership for higher-value ingredients; approvals needed.

What just happened

Sanstar Limited's Board of Directors approved a preferential issue of equity shares to Corn Products Development Inc., a wholly owned subsidiary of Ingredion Incorporated, for approximately ₹198.3 crore. The issue price is ₹110 per equity share.

Concurrently, Sanstar signed a shareholders' agreement with Ingredion India Private Limited and Amishi Drugs and Chemicals Private Limited to form a Joint Venture (JV) in India. This JV will focus on manufacturing, selling, and distributing specialty pharmaceutical excipients and other specialty ingredient products.

Both the preferential issue and the JV formation are subject to shareholder and stock exchange approvals.

Why this matters

This strategic move is expected to provide Sanstar with access to Ingredion's global R&D, technical expertise, and technology transfer in areas like advanced starch derivatives and plant-based ingredients. It aims to strengthen Sanstar's balance sheet, support capacity expansion, and diversify its business into higher-value specialty pharmaceutical ingredients.

The backstory

Sanstar recently increased its installed capacity from 1,100 TPD to 2,350 TPD with the commissioning of a new facility at its Dhule plant. This expansion is key to scaling operations and meeting increased market demand.

The JV, once operational, targets commercial activities within 30 to 36 months. Ingredion will contribute proprietary technology and global know-how, while Sanstar brings local manufacturing and regulatory expertise.

What changes now

If approvals are secured, Sanstar will gain a significant global investor in Ingredion, bolstering its financial standing and strategic direction. The JV will open new avenues in the specialty pharmaceutical ingredients market, potentially enhancing margins and market reach.

Risks to watch

The primary risks involve the successful acquisition of shareholder and regulatory approvals for both the preferential issue and the JV. Delays or failure to secure these approvals could impact the deal's completion and Sanstar's growth plans.

Peer comparison

Ingredion Incorporated is a global player in the ingredient solutions market. Sanstar's move into specialty pharmaceutical excipients aligns with broader industry trends towards higher-value, specialized ingredients. Details on specific peers in the Indian specialty pharmaceutical excipient market are not provided in the filing.

Context metrics (time-bound)

• Preferential Issue Size: ₹198.3 crore
• Issue Price: ₹110 per equity share
• Post-issue stake for Ingredion subsidiary: Approx. 9.0%
• Current installed capacity: 2,350 TPD (up from 1,100 TPD)
• JV Commercial Operations Target: 30-36 months post-incorporation